These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 33986603)

  • 21. Assessing the Value of Sarilumab Monotherapy for Adults with Moderately to Severely Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis.
    Whittington MD; McQueen RB; Ollendorf DA; Chapman RH; Kumar VM; Synnott PG; Agboola F; Campbell JD
    J Manag Care Spec Pharm; 2019 Jan; 25(1):80-87. PubMed ID: 30589626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-Effectiveness Modeling of Prostate-Specific Membrane Antigen Positron Emission Tomography with Piflufolastat F 18 for the Initial Diagnosis of Patients with Prostate Cancer in the United States.
    Yee CW; Harvey MJ; Xin Y; Kirson NY
    Pharmacoeconomics; 2024 Feb; 42(2):231-247. PubMed ID: 37934376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Demographics, treatment patterns, and healthcare utilization and cost of repository corticotropin injection in patients with systemic lupus erythematosus or rheumatoid arthritis.
    Wu B; Deshpande G; Gu T; Popelar B; Philbin M; Wan GJ
    J Med Econ; 2017 Nov; 20(11):1170-1177. PubMed ID: 28760047
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity.
    Prawjaeng J; Leelahavarong P; Budtarad N; Pilasant S; Chanjam C; Katchamart W; Narongroeknawin P; Kitumnuaypong T
    BMC Health Serv Res; 2023 May; 23(1):561. PubMed ID: 37259090
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of Tofacitinib in the Treatment of Moderate to Severe Rheumatoid Arthritis in South Korea.
    Lee MY; Park SK; Park SY; Byun JH; Lee SM; Ko SK; Lee EK
    Clin Ther; 2015 Aug; 37(8):1662-76.e2. PubMed ID: 26243076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial.
    Marsden J; Kelleher M; Gilvarry E; Mitcheson L; Bisla J; Cape A; Cowden F; Day E; Dewhurst J; Evans R; Hardy W; Hearn A; Kelly J; Lowry N; McCusker M; Murphy C; Murray R; Myton T; Quarshie S; Vanderwaal R; Wareham A; Hughes D; Hoare Z
    EClinicalMedicine; 2023 Dec; 66():102311. PubMed ID: 38045803
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is SABR Cost-Effective in Oligometastatic Cancer? An Economic Analysis of the SABR-COMET Randomized Trial.
    Qu XM; Chen Y; Zaric GS; Senan S; Olson RA; Harrow S; John-Baptiste A; Gaede S; Mulroy LA; Schellenberg D; Senthi S; Swaminath A; Kopek N; Liu M; Warner A; Rodrigues GB; Palma DA; Louie AV
    Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1176-1184. PubMed ID: 33309977
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of stent-retriever thrombectomy in large vessel occlusion strokes of the anterior circulation: Analysis from the French societal perspective.
    Barral M; Armoiry X; Boudour S; Aulagner G; Schott AM; Turjman F; Gory B; Viprey M
    Rev Neurol (Paris); 2020 Mar; 176(3):180-188. PubMed ID: 31526554
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer.
    Sun L; Brentnall A; Patel S; Buist DSM; Bowles EJA; Evans DGR; Eccles D; Hopper J; Li S; Southey M; Duffy S; Cuzick J; Dos Santos Silva I; Miners A; Sadique Z; Yang L; Legood R; Manchanda R
    JAMA Oncol; 2019 Dec; 5(12):1718-1730. PubMed ID: 31580391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK.
    Gani R; Giovannoni G; Bates D; Kemball B; Hughes S; Kerrigan J
    Pharmacoeconomics; 2008; 26(7):617-27. PubMed ID: 18563952
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal Trial.
    Fleischmann R; Furst DE; Connolly-Strong E; Liu J; Zhu J; Brasington R
    Rheumatol Ther; 2020 Jun; 7(2):327-344. PubMed ID: 32185745
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of Triple Therapy vs. Biologic Treatment Sequence as First-line Therapy for Rheumatoid Arthritis Patients after Methotrexate Failure.
    Li S; Li J; Peng L; Li Y; Wan X
    Rheumatol Ther; 2021 Jun; 8(2):775-791. PubMed ID: 33772743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of Recurrent Dupuytren Contracture Treatment.
    Yoon AP; Kane RL; Hutton DW; Chung KC
    JAMA Netw Open; 2020 Oct; 3(10):e2019861. PubMed ID: 33030553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety of repository corticotropin injection as an adjunctive therapy for the treatment of rheumatoid arthritis.
    Fleischmann R; Furst DE
    Expert Opin Drug Saf; 2020 Aug; 19(8):935-944. PubMed ID: 32497440
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-Effectiveness Analysis of Abatacept Compared with Adalimumab on Background Methotrexate in Biologic-Naive Adult Patients with Rheumatoid Arthritis and Poor Prognosis.
    Alemao E; Johal S; Al MJ; Rutten-van Mölken M
    Value Health; 2018 Feb; 21(2):193-202. PubMed ID: 29477401
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modelling the cost-effectiveness of combination therapy for early, rapidly progressing rheumatoid arthritis by simulating the reversible and irreversible effects of the disease.
    Stephens S; Botteman MF; Cifaldi MA; van Hout BA
    BMJ Open; 2015 Jun; 5(6):e006560. PubMed ID: 26059521
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for Treatment of Patients With Intermediate- to High-Risk Diffuse Large B-Cell Lymphoma.
    Vijenthira A; Kuruvilla J; Crump M; Jain M; Prica A
    J Clin Oncol; 2023 Mar; 41(8):1577-1589. PubMed ID: 36315922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-Effectiveness of Operative Versus Nonoperative Management of Patients With Intra-articular Calcaneal Fractures.
    Albin SR; Bellows BK; Van Boerum DH; Hunter S; Koppenhaver SL; Nelson RE; Marcus R; Dibble L; Cornwall M; Fritz JM
    J Orthop Trauma; 2020 Jul; 34(7):382-388. PubMed ID: 31917759
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-Effectiveness Analysis of Stereotactic Ablative Body Radiotherapy for the Treatment of Oligometastatic Tumors versus Standard of Care.
    Raymakers AJN; Cameron D; Tyldesley S; Regier DA
    Curr Oncol; 2021 May; 28(3):1857-1866. PubMed ID: 34068400
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece.
    Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsapas A; Kourlaba G; Papageorgiou G; Maniadakis N
    Clin Drug Investig; 2018 May; 38(5):417-426. PubMed ID: 29349708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.